Hanieh Taheri

Ms. Hanieh Taheri

The Ohio State University, Columbus, Georgia, USA
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2024 in Journal of Chromatography B
Verified
Journal Article
Open access
HTHanieh Taheri
Hanieh Taheri
YJYan Jin
Yan Jin
EAEman Ahmed
Eman Ahmed
PHPeng Hu
Peng Hu
YLYang Li
Yang Li
SHShuiying Hu
Shuiying Hu
A liquid chromatography - electrospray ionization-mass spectrometry (LC-ESI-MS) method was developed for the quantification of letrozole, a third-generation aromatase inhibitor, and its main carbinol metabolite (CM) in support of murine pharmacokinetic studies. Using polarity switching, simultaneous ESI-MS measurement of letrozole and CM was achieved in positive and negative mode, respectively. The assay procedure involved a one-step protein precipitation and extraction of all analytes from mouse plasma requiring only 5 μL of sample. Separation was optimized on an Accucore aQ column with gradient elution at a flow rate of 0.4 mL/min in 5 min. Two calibration curves per day over four consecutive measurement days showed satisfactory linear responses (r2 > 0.99) over concentration ranges of 5-1000 ng/mL and 20-2000 ng/mL for letrozole and CM, respectively. No matrix effect was found, and the mean extraction recoveries were 103-108 % for letrozole and 99.8-107 % for CM. Precision and accuracy within a single run and over four consecutive measurement days were verified to be within acceptable limits. Application of the developed method to preclinical pharmacokinetic studies in mice receiving oral letrozole at a dose 1 or 10 mg/kg revealed that the systemic exposure to letrozole was dose-, formulation-, and strain-dependent. These findings may inform the future design of preclinical studies aimed at refining the pharmacological profile of this clinically important drug.

1 March 2025 in Cancer Research Communications
Verified
Journal Article
Open access
HTHanieh Taheri
Hanieh Taheri
Yang LiYang Li
Yang Li
KHKevin M. Huang
Kevin M. Huang
EAEman Ali Abdelnaby Ahmed
Eman Ali Abdelnaby Ahmed
YJYan Jin
Yan Jin
SHShuiying Hu
Shuiying Hu
Aromatase inhibitors (AI) such as anastrozole, letrozole, and exemestane are used as adjuvant treatment for postmenopausal women with hormone receptor–positive breast cancer. The interindividual pharmacokinetic variability seen with AIs is extensive, and this phenomenon may have important ramification for AI-associated arthralgia, a common toxicity of which the etiology remains unclear. We speculated that hepatic uptake transporters involved in the elimination of AIs play a crucial role in explaining this pharmacologic variability. Using an array of in silico, in vitro, in vivo, and human studies, we identified OATP1B1 and OATP1B3 (in humans) as well as the murine ortholog Oatp1b2 as transporters that regulate the initial step in the elimination of AIs. Genetic deficiency of this transport mechanism in mice was associated with elevated plasma levels of AIs and with concurrent increases in treatment-related arthralgia. In line with these findings, we found that low hepatic OATP1B-type transporter activity in patients with breast cancer was associated with an increase in AI-associated arthralgia. These findings shed light on the rate-limiting step in the elimination of AIs and suggest a rationale for the potential implementation of transporter biomarkers to predict susceptibility to AI-associated arthralgia and ultimately mitigate this debilitating toxicity. Significance: AIs are effective but often discontinued because of arthralgia. This study explores the role of OATP1B transporters in AI-related side effects and the potential usage of transporter biomarkers to predict and reduce the risk of arthralgia associated with AI treatment.

24 March 2025 in Molecules
Verified
Journal Article
Open access
PDF file
HTHanieh Taheri
Hanieh Taheri
EAEman Ali Abdelnaby Ahmed
Eman Ali Abdelnaby Ahmed
PHPeng Hu
Peng Hu
ASAlex Sparreboom
Alex Sparreboom
SHShuiying Hu
Shuiying Hu
Exemestane, a steroidal aromatase inhibitor prescribed for post-menopausal women with estrogen receptor-positive breast cancer, is associated with debilitating musculoskeletal side effects and exhibits considerable interindividual variability in systemic exposure. Although exemestane is metabolized mainly by cytochrome P-450 3A4, the contribution of this metabolic pathway to the elimination of exemestane and its drug–drug interaction liabilities remains uncertain. Here, we developed a novel quantification method for exemestane and applied it to evaluate the role of CYP3A-mediated metabolism in the pharmacokinetics of exemestane using wild-type and Cyp3a-deficient mice. Liquid chromatography–mass spectrometry was used to quantify exemestane in selective reaction monitoring (SRM) mode, in which precursor ion and fragment ion data were obtained simultaneously. Validation results demonstrated that the developed method was accurate and precise, and sufficiently sensitive to be applied to murine pharmacokinetic studies involving serial blood sampling strategies. Although in vitro studies indicate that exemestane undergoes extensive metabolism in the liver to inactive metabolites by CYP3A4, complete Cyp3a deficiency in mice did not influence the systemic exposure to exemestane. This unequivocal evidence from genetic approaches using preclinical mouse models confirms that the potential for such DDI liabilities is very low. Our newly developed method provides a robust platform for further pharmacokinetic studies with exemestane in mice to delineate DDI liabilities and define the mechanisms of elimination.

13 May 2025
Verified
Other
Open access
HTHanieh Taheri
Hanieh Taheri
Yang LiYang Li
Yang Li
KHKevin M. Huang
Kevin M. Huang
EAEman Ali Abdelnaby Ahmed
Eman Ali Abdelnaby Ahmed
YJYan Jin
Yan Jin
SHShuiying Hu
Shuiying Hu
Figure S2 from OATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor–Associated Arthralgia Susceptibility

28 March 2025
Verified
Other
Open access
HTHanieh Taheri
Hanieh Taheri
Yang LiYang Li
Yang Li
KHKevin M. Huang
Kevin M. Huang
EAEman Ali Abdelnaby Ahmed
Eman Ali Abdelnaby Ahmed
YJYan Jin
Yan Jin
SHShuiying Hu
Shuiying Hu
Figure S6 from OATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor–Associated Arthralgia Susceptibility

28 March 2025
Verified
Other
Open access
HTHanieh Taheri
Hanieh Taheri
Yang LiYang Li
Yang Li
KHKevin M. Huang
Kevin M. Huang
EAEman Ali Abdelnaby Ahmed
Eman Ali Abdelnaby Ahmed
YJYan Jin
Yan Jin
SHShuiying Hu
Shuiying Hu
Figure S2 from OATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor–Associated Arthralgia Susceptibility